RVMD Stock Analysis: Revolution Medicines | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 41.631m USD | 12M Return: 241% | US76155X1000 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 336M
Qual. Beats: -5
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 6.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Revolution Medicines, Inc. (NASDAQ: RVMD) is a clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers. The companys pipeline centers on two main approaches: RAS(ON) inhibitors that bind RAS variants for use as monotherapy or in combinations, and RAS companion inhibitors designed to suppress cooperating targets and pathways that sustain these cancers. Headquartered in Redwood City, California, and incorporated in 2014, Revolution Medicines has been publicly traded since its February 2020 IPO and operates within the biotechnology subsector of healthcare, where clinical-stage companies typically rely on capital markets and partnership funding to advance drug candidates through lengthy development cycles before any potential commercial revenue.
The companys lead clinical programs include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) for solid tumors, and zoldonrasib G12D (RMC-9805), with a Phase 3 registrational trial underway evaluating daraxonrasib in combination with zoldonrasib in first-line pancreatic ductal adenocarcinoma (PDAC). Earlier-stage candidates include RMC-5127 (G12V) and RMC-0708 (Q61H) in clinical trials, along with RMC-8839 (G13C). The focus on RAS mutations is notable because these genetic drivers are among the most common oncogenic alterations in human cancers, historically considered difficult drug targets, making the companys RAS(ON) inhibitor platform a differentiated approach within the precision oncology landscape.
- Phase 3 daraxonrasib data in pancreatic cancer due
- Elevated R&D cash burn as three pivotal trials advance
- KRAS competition from Amgen and Mirati pressures pipeline value
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.34 > 0.02 and ΔFCF/TA -4.12 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.28 > 3% & CFO -1.22b > Net Income -1.77b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 11.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (210.9m) vs 12m ago 12.09% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 10.77%; Δ -10.77% > 0%) |
| Interest Coverage Ratio: -28.80 > 6 (EBIT TTM -1.71b / Interest Expense TTM 59.3m) |
| A: 0.85 (Total Current Assets 4.03b - Total Current Liabilities 354.1m) / Total Assets 4.32b |
| B: -0.92 (Retained Earnings -3.97b / Total Assets 4.32b) |
| C: -0.51 (EBIT TTM -1.71b / Avg Total Assets 3.38b) |
| D: 1.52 (Book Value of Equity 2.61b / Total Liabilities 1.72b) |
| Altman-Z'' = 0.78 = B |
As of November 06, 2026, the stock is trading at USD 199.70 with a total of 2,494,920 shares traded. Over the past week, the price has changed by +5.82%, over one month by -3.84%, over three months by +3.23% and over the past year by +240.96%.
Current recommended Stop Loss: 188.60 (which is 5.6% or 1.4 ATR below the current price).
Revolution Medicines has received a consensus analysts rating of 4.72. Therefore, it is recommended to buy RVMD.
- StrongBuy: 19
- Buy: 5
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 258.8 | 29.6% |
P/S = 9035.0954
P/B = 15.4775
Revenue TTM = 0.0 USD
EBIT TTM = -1.71b USD
EBITDA TTM = -1.69b USD
Long Term Debt = 487.4m USD (from longTermDebt, last quarter)
Short Term Debt = 16.8m USD (from shortTermDebt, last quarter)
Debt = 796.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 154.5m
Net Debt = -2.45b USD (calculated: Debt 796.4m - CCE 3.25b)
Enterprise Value = 39.2b USD (41.6b + Debt 796.4m - CCE 3.25b)
Interest Coverage Ratio = -28.80 (Ebit TTM -1.71b / Interest Expense TTM 59.3m)
EV/FCF = -26.96x (Enterprise Value 39.2b / FCF TTM -1.45b)
FCF Yield = -3.71% (FCF TTM -1.45b / Enterprise Value 39.2b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 16.6m) / Revenue TTM)
Tobins Q-Ratio = 9.06 (Enterprise Value 39.2b / Total Assets 4.32b)
Interest Expense / Debt = 7.45% (Interest Expense 59.3m / Debt 796.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -1.35b (EBIT -1.71b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.10 (Total Current Assets 4.03b / Total Current Liabilities 442.5m)
Debt / Equity = 0.31 (Debt 796.4m / totalStockholderEquity, last quarter 2.61b)
Debt / EBITDA = 1.45 (negative EBITDA) (Net Debt -2.45b / EBITDA -1.69b)
Debt / FCF = 1.69 (negative FCF - burning cash) (Net Debt -2.45b / FCF TTM -1.45b)
Total Stockholder Equity = 1.83b (last 4 quarters mean from totalStockholderEquity)
RoA = -52.37% (Net Income -1.77b / Total Assets 4.32b)
RoE = -96.44% (Net Income TTM -1.77b / Total Stockholder Equity 1.83b)
RoCE = -73.63% (EBIT -1.71b / Capital Employed (Equity 1.83b + L.T.Debt 487.4m))
RoIC = -33.87% (negative operating profit) (NOPAT -1.35b / Invested Capital 3.99b)
WACC = 10.10% (E(41.6b)/V(42.4b) * Re(10.18%) + D(796.4m)/V(42.4b) * Rd(7.45%) * (1-Tc(0.21)))
Discount Rate = 10.18% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.03 | Cagr: 11.61%
[DCF] Fair Price = unknown (Cash Flow -1.45b)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -3.03 | # QB: -5
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -1.65 | # QB: -1
EPS current Quarter (2026-09-30): EPS=-2.38 | Chg30d=+0.82% | Revisions=+38% | Analysts=21
EPS current Year (2026-12-31): EPS=-9.58 | Chg30d=+1.26% | Revisions=+30% | GrowthEPS=-61.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-5.76 | Chg30d=+5.75% | Revisions=+38% | GrowthEPS=+39.8% | GrowthRev=+526.6%
[Analyst] Revisions Ratio: +45% (up=13, down=4)